biostudies-literatureJanssen QPZonMwKWF Kankerbestrijding300https://www.ebi.ac.uk/biostudies/studies/S-EPMC7989075biostudies-literatureUnknown21(1)<h4>Background</h4>Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant BMC cancerTotal neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.PMC798907510955843004108Zonderhuis BMWilmink JWGroot Koerkamp BLoosveld OJLJanssen QPKarsten TMvan Dam JLPatijn GAde Hingh IHJTBosscha KPvan Santvoort HCBos HBesselink MGCoene PPLOvan Eijck CHJvan der Kolk MBLiem MSLHoms MYVBonsing BAde Vos-Geelen JDutch Pancreatic Cancer Groupvan Tienhoven GfalseTotal neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.<h4>Background</h4>Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant 2021-01-01T00:00:00Z2021 Mar2026-05-07T17:46:23.576Z2025-04-04T22:01:35.928ZS-EPMC79890753375744010.1186/s12885-021-08031-z